FALSE000182429300018242932024-09-062024-09-06

Image_0.jpg

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 6, 2024
Image_8.jpg
GRI BIO, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4003482-4369909
(State or other jurisdiction(Commission File Number)(IRS Employer Identification No.)
of incorporation)
2223 Avenida de la Playa, Suite 208
La Jolla, CA 92037
(Address of principal executive offices and zip code)
(619) 400-1170
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)
Image_8.jpg
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
GRI
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging Growth Company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Image_0.jpg

Image_8.jpg



Item 5.07 Submission of Matters to a Vote of Security Holders
On September 6, 2024, GRI Bio, Inc. (the “Company”) reconvened its 2024 Annual Meeting of Stockholders (the “Annual Meeting”), which was previously convened and adjourned on August 23, 2024, virtually at www.virtualshareholdermeeting.com/GRI2024. Of the Company’s 741,914 shares of common stock issued and outstanding and eligible to vote as of the record date of June 27, 2024, a quorum of 311,668 shares, or approximately 42% of the eligible shares, was present in person or represented by proxy at the Annual Meeting. Each of the matters set forth below is described in detail in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on August 2, 2024, as amended and supplemented to date. The following actions were taken at the Annual Meeting:

Proposal 1
Election of David Baker to the Company's Board of Directors, to serve as Class I director until the Company’s 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified.
Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
61,13440,091155210,288
Proposal 2
Ratification of the appointment of Sadler, Gibb & Associates LLC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
285,64125,98839—
Proposal 3
Approval, for purposes of complying with Nasdaq Rule 5635(d), of the issuance of shares of the Company’s common stock, par value $0.0001 per share (the "Common Stock"), underlying Series C-1 Common Warrants and Series C-2 Common Warrants issued by the Company pursuant to that certain Securities Purchase Agreement, dated as of June 26, 2024, by and between the Company and the investor named on the signature page thereto, and underlying Placement Agent Warrants issued by the Company pursuant to that certain Engagement Letter between the Company and H.C. Wainwright & Co., LLC, dated as of May 3, 2024, in an aggregate amount equal to or in excess of 20% of the Company’s Common Stock then outstanding.
Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
51,16547,9712,244210,288
Proposal 4
Approval of an amendment to the Company’s Amended and Restated 2018 Equity Incentive Plan, as amended, to increase the aggregate number of shares of Common Stock available for issuance thereunder by 600,000.
Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
31,55668,911913210,288



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 6, 2024GRI Bio, Inc.
By: /s/ Leanne Kelly
Leanne Kelly
Chief Financial Officer



v3.24.2.u1
Cover
Sep. 06, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Sep. 06, 2024
Entity Registrant Name GRI BIO, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40034
Entity Tax Identification Number 82-4369909
Entity Address, Address Line One 2223 Avenida de la Playa
Entity Address, Address Line Two Suite 208
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code 619
Local Phone Number 400-1170
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol GRI
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001824293
Amendment Flag false
Document Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001824293
Vallon Pharmaceuticals (NASDAQ:VLON)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Vallon Pharmaceuticals Charts.
Vallon Pharmaceuticals (NASDAQ:VLON)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Vallon Pharmaceuticals Charts.